News

Search For News


TRY IT NOW

Sign up online today & collaborate

or click here to find out more

Search results for {{term}}

1. Oxford BioMedica and Green Cross LabCell Form a Partnership to Develop

Oxford BioMedica and Green Cross LabCell Form a Partnership to Develop Gene-modified NK Cell Therapeutics in Cancer 02/06/2016Unique combination of Oxford BioMedica’s LentiVector® delivery platform and Green Cross LabCell’s NK cell platform to generate a pipeline of differentiated products in cancerOxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE: OXB), a leading gene and cell therapy group, today announces that it has entered into a Res


2.  Melissa Gardiner Joins Consilium Strategic Communications from AstraZ

 Melissa Gardiner Joins Consilium Strategic Communications from AstraZeneca06/06/2016Consilium Strategic Communications, a global leader in strategic healthcare communications, today welcomes Melissa Gardiner from AstraZeneca's global media relations team.Melissa joins Consilium as an Executive Consultant having gained four years' broad experience in global media relations, social media and digital communications at the FTSE 100 pharmaceuticals leader, AstraZeneca.Mary-Jane Elliott, Managin


3. Mereo BioPharma: Proposed Admission to Trading on AIM and a Further Ca

Mereo BioPharma: Proposed Admission to Trading on AIM and a Further Capital Raise of £14.8m 06/06/2016 London, UK – Mereo, a UK-based specialty biopharmaceutical company, is pleased to announce that it expects Admission of its Ordinary Shares to trading on AIM to take effect on 9 June 2016. The Company has also completed a supplementary Capital Raise with total gross proceeds of £14.8 million comprised of a private placement of its Ordinary Shares raising gross proceeds


4. Eurofins Lancaster Laboratories Announces Major Expansion Plans to Enh

Eurofins Lancaster Laboratories Announces Major Expansion Plans to Enhance Its Laboratory Services Footprint and Create New Jobs in Ireland 13/06/2016Eurofins Lancaster Laboratories, part of Eurofins Scientific (EUFI.PA), the world leader in bioanalytical testing, announces strategic plans for the expansion of its Dungarvan, Ireland campus, including development of a new building as well as expansion of its current facility. Further, as a major employer in the South East of Ireland, Eurofin


5. First Patient Enrolled in Summit’s PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Boys with DMD

First Patient Enrolled in Summit’s PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Boys with DMD 17/06/2016Oxford, UK – Summit Therapeutics plc , the drug discovery and development company advancing therapies for Duchenne muscular dystrophy (‘DMD’) andEzutromid is an orally administered small molecule that is designed to modulate utrophin, a protein that is structurally and functionally similar to the dystrophin protein. Dystrophin is essential for t



Page 13 of 30 ( 148 results in total )
© Catalyst Innovation Portal 2019